760 related articles for article (PubMed ID: 28262554)
21. Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab.
Frerichs KA; Broekmans MEC; Marin Soto JA; van Kessel B; Heymans MW; Holthof LC; Verkleij CPM; Boominathan R; Vaidya B; Sendecki J; Axel A; Gaudet F; Pillarisetti K; Zweegman S; Adams HC; Mutis T; van de Donk NWCJ
Clin Cancer Res; 2020 May; 26(9):2203-2215. PubMed ID: 31969333
[TBL] [Abstract][Full Text] [Related]
22. The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma.
Davis JA; Shockley A; Hashmi H
J Oncol Pharm Pract; 2022 Jun; 28(4):960-968. PubMed ID: 35006032
[TBL] [Abstract][Full Text] [Related]
23. BCMAxCD3 Bispecific Yields Robust Responses in Myeloma.
Cancer Discov; 2023 Jun; 13(6):1280. PubMed ID: 37075091
[TBL] [Abstract][Full Text] [Related]
24. Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2021.
Demel I; Bago JR; Hajek R; Jelinek T
Br J Haematol; 2021 May; 193(4):705-722. PubMed ID: 33216972
[TBL] [Abstract][Full Text] [Related]
25. BCMA-targeted immunotherapy for multiple myeloma.
Yu B; Jiang T; Liu D
J Hematol Oncol; 2020 Sep; 13(1):125. PubMed ID: 32943087
[TBL] [Abstract][Full Text] [Related]
26. Gene therapy with B-cell maturation antigen/CD3 bispecific antibody encoding plasmid DNA for treating multiple myeloma.
Peng F; Wang Y; Zhao J; Liu H; Liu Z; Ding K; Zhang H; Fu R
Br J Haematol; 2023 May; 201(3):417-421. PubMed ID: 35594370
[TBL] [Abstract][Full Text] [Related]
27. Bispecific T-cell engagers for treatment of multiple myeloma.
Ravi G; Costa LJ
Am J Hematol; 2023 Mar; 98 Suppl 2():S13-S21. PubMed ID: 35702871
[TBL] [Abstract][Full Text] [Related]
28. Blockade of VLA4 sensitizes leukemic and myeloma tumor cells to CD3 redirection in the bone marrow microenvironment.
Nair-Gupta P; Rudnick SI; Luistro L; Smith M; McDaid R; Li Y; Pillarisetti K; Joseph J; Heidrich B; Packman K; Attar R; Gaudet F
Blood Cancer J; 2020 Jun; 10(6):65. PubMed ID: 32483120
[TBL] [Abstract][Full Text] [Related]
29. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.
Brudno JN; Maric I; Hartman SD; Rose JJ; Wang M; Lam N; Stetler-Stevenson M; Salem D; Yuan C; Pavletic S; Kanakry JA; Ali SA; Mikkilineni L; Feldman SA; Stroncek DF; Hansen BG; Lawrence J; Patel R; Hakim F; Gress RE; Kochenderfer JN
J Clin Oncol; 2018 Aug; 36(22):2267-2280. PubMed ID: 29812997
[TBL] [Abstract][Full Text] [Related]
30. Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibody.
Raab MS; Cohen YC; Schjesvold F; Aardalen K; Oka A; Spencer A; Wermke M; Souza AD; Kaufman JL; Cafro AM; Ocio EM; Doki N; Henson K; Trabucco G; Carrion A; Bender FC; Juif PE; Fessehatsion A; Fan L; Stonehouse JP; Blankenship JW; Granda B; De Vita S; Lu H
Leukemia; 2023 Jun; 37(6):1349-1360. PubMed ID: 37024520
[TBL] [Abstract][Full Text] [Related]
31. Invariant NKT cells dictate antitumor immunity elicited by a bispecific antibody cotargeting CD3 and BCMA.
Casey M; Tu C; Harrison SJ; Nakamura K
Blood Adv; 2022 Sep; 6(17):5165-5170. PubMed ID: 35830292
[TBL] [Abstract][Full Text] [Related]
32. γ-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation.
Chen H; Yu T; Lin L; Xing L; Cho SF; Wen K; Aardalen K; Oka A; Lam J; Daley M; Lu H; Munshi N; Anderson KC; Tai YT
Blood Cancer J; 2022 Aug; 12(8):118. PubMed ID: 35973981
[TBL] [Abstract][Full Text] [Related]
33. Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma.
Bilich T; Nelde A; Bauer J; Walz S; Roerden M; Salih HR; Weisel K; Besemer B; Marcu A; Lübke M; Schuhmacher J; Neidert MC; Rammensee HG; Stevanović S; Walz JS
Blood Cancer J; 2020 Feb; 10(2):24. PubMed ID: 32111817
[TBL] [Abstract][Full Text] [Related]
34. AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys.
Goldstein RL; Goyos A; Li CM; Deegen P; Bogner P; Sternjak A; Thomas O; Klinger M; Wahl J; Friedrich M; Rattel B; Lamas E; Min X; Sudom A; Farshbaf M; Coxon A; Balazs M; Arvedson T
Blood Adv; 2020 Sep; 4(17):4180-4194. PubMed ID: 32886754
[TBL] [Abstract][Full Text] [Related]
35. The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma.
Duan D; Wang K; Wei C; Feng D; Liu Y; He Q; Xu X; Wang C; Zhao S; Lv L; Long J; Lin D; Zhao A; Fang B; Jiang J; Tang S; Gao J
Front Immunol; 2021; 12():609421. PubMed ID: 33767695
[TBL] [Abstract][Full Text] [Related]
36. Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing.
Li J; Stagg NJ; Johnston J; Harris MJ; Menzies SA; DiCara D; Clark V; Hristopoulos M; Cook R; Slaga D; Nakamura R; McCarty L; Sukumaran S; Luis E; Ye Z; Wu TD; Sumiyoshi T; Danilenko D; Lee GY; Totpal K; Ellerman D; Hötzel I; James JR; Junttila TT
Cancer Cell; 2017 Mar; 31(3):383-395. PubMed ID: 28262555
[TBL] [Abstract][Full Text] [Related]
37. B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma.
Tai YT; Anderson KC
Expert Opin Biol Ther; 2019 Nov; 19(11):1143-1156. PubMed ID: 31277554
[No Abstract] [Full Text] [Related]
38. Effective anti-BCMA retreatment in multiple myeloma.
Gazeau N; Beauvais D; Yakoub-Agha I; Mitra S; Campbell TB; Facon T; Manier S
Blood Adv; 2021 Aug; 5(15):3016-3020. PubMed ID: 34351389
[TBL] [Abstract][Full Text] [Related]
39. Preclinical efficacy and pharmacokinetics of an RNA-encoded T cell-engaging bispecific antibody targeting human claudin 6.
Stadler CR; Ellinghaus U; Fischer L; Bähr-Mahmud H; Rao M; Lindemann C; Chaturvedi A; Scharf C; Biermann I; Hebich B; Malz A; Beresin G; Falck G; Häcker A; Houben A; Erdeljan M; Wolf K; Kullmann M; Chang P; Türeci Ö; Şahin U
Sci Transl Med; 2024 May; 16(748):eadl2720. PubMed ID: 38776391
[TBL] [Abstract][Full Text] [Related]
40. BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice.
Zhou X; Rasche L; Kortüm KM; Mersi J; Einsele H
Haematologica; 2023 Apr; 108(4):958-968. PubMed ID: 36263838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
